290 related articles for article (PubMed ID: 2886642)
1. Effects of ORF 17583, other histamine H2-receptor antagonists and omeprazole on gastric acid secretory states in rats and dogs.
Katz LB; Tobia AJ; Shriver DA
J Pharmacol Exp Ther; 1987 Aug; 242(2):437-42. PubMed ID: 2886642
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of ORF 17578, a new histamine H2-receptor antagonist: comparison with cimetidine and ranitidine.
Katz LB; Scott CK; Shriver DA
J Pharmacol Exp Ther; 1986 May; 237(2):404-10. PubMed ID: 2871172
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine.
Katz LB; Scott CK; Shriver DA
J Pharmacol Exp Ther; 1986 Aug; 238(2):587-93. PubMed ID: 2874214
[TBL] [Abstract][Full Text] [Related]
4. A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.
Cavanagh RL; Usakewicz JJ; Buyniski JP
J Pharmacol Exp Ther; 1983 Jan; 224(1):171-9. PubMed ID: 6129316
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the H2 receptor antagonist and gastric acid antisecretory properties of Wy-45,727.
Nielsen ST
J Pharmacol Exp Ther; 1987 Aug; 242(2):607-13. PubMed ID: 2886646
[TBL] [Abstract][Full Text] [Related]
6. Selective gastric antilesion properties of rioprostil, a prostaglandin E1 analog, in rats and dogs.
Katz LB; Shriver DA; Tobia AJ; Rosenthale ME
J Pharmacol Exp Ther; 1987 Sep; 242(3):927-33. PubMed ID: 3116199
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of gastric acid secretion by omeprazole in the dog and rat.
Larsson H; Carlsson E; Junggren U; Olbe L; Sjöstrand SE; Skånberg I; Sundell G
Gastroenterology; 1983 Oct; 85(4):900-7. PubMed ID: 6884713
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of ranitidine, famotidine and omeprazole on plasma gastrin in the rat.
Decktor DL; Pendleton RG; Kellner AT; Davis MA
J Pharmacol Exp Ther; 1989 Apr; 249(1):1-5. PubMed ID: 2565384
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of the gastric antisecretory activity of histamine H2-receptor antagonists by clebopride.
Fernández AG; Massingham R; Roberts DJ
Methods Find Exp Clin Pharmacol; 1988 May; 10(5):285-93. PubMed ID: 2899659
[TBL] [Abstract][Full Text] [Related]
10. Effects of the new H2-receptor antagonist 3-amino-4-[4- [4- (1-piperidinomethyl)-2-pyridyloxy]-cis-2-butenylamino]-3-cyclobutene-1, 2- dione hydrochloride on gastric acid secretion and ulceration.
Muramatsu M; Isobe Y; Arai I; Hirose-Kijima H; Usuki-Ito C; Nagai H; Aihara H; Otomo S
Arzneimittelforschung; 1990 Jan; 40(1):49-54. PubMed ID: 1971169
[TBL] [Abstract][Full Text] [Related]
11. The effect of secretagogue selection on potency determinations for gastric acid antisecretory agents.
Palumbo GJ; Nielsen ST
Methods Find Exp Clin Pharmacol; 1988 Mar; 10(3):151-5. PubMed ID: 2898575
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of mifentidine, a novel H2-receptor antagonist.
Pagani F; Micheletti R; Brambilla A; Schiavone A; Montagna E; Ciprandi C; Giachetti A
Arzneimittelforschung; 1985; 35(1A):451-5. PubMed ID: 2859036
[TBL] [Abstract][Full Text] [Related]
13. Gastric antisecretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs.
Shibata M; Yamaura T; Inaba N; Onodera S; Chida Y; Ohnishi H
Eur J Pharmacol; 1993 Apr; 235(2-3):245-53. PubMed ID: 8099553
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea.
Sekiguchi H; Hamada K; Kobayashi F; Taga F; Uchida H
Arzneimittelforschung; 1993 Feb; 43(2):129-33. PubMed ID: 8096132
[TBL] [Abstract][Full Text] [Related]
15. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.
Lin TM; Evans DC; Warrick MW; Pioch RP
J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081
[TBL] [Abstract][Full Text] [Related]
16. Antisecretory and antiulcer activities of a potent new histamine H2-receptor antagonist with an intermediate duration of action.
Borella L; Russell J; Rimele TJ; Grimes D; Failli A; Mir GN
Arzneimittelforschung; 1988 Mar; 38(3):366-72. PubMed ID: 2898247
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological regulation of gastric acid secretion in the apical membrane of parietal cells; a new target for antisecretory drugs.
Okabe S; Shimosako K; Amagase K
J Physiol Pharmacol; 2001 Dec; 52(4 Pt 1):639-56. PubMed ID: 11787764
[TBL] [Abstract][Full Text] [Related]
18. Antisecretory effects of a novel and long-lasting histamine H2-receptor antagonist, YM-14471, in rats and dogs.
Yuki H; Kamato T; Nishida A; Fujihara A; Takeda M; Miyata K
Jpn J Pharmacol; 1993 Nov; 63(3):345-51. PubMed ID: 7906319
[TBL] [Abstract][Full Text] [Related]
19. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
20. Effects of H2-receptor antagonists upon physiological acid secretory states in animals.
Pendleton RG; Cook PG; Shepherd-Rose A; Mangel AW
J Pharmacol Exp Ther; 1985 Apr; 233(1):64-9. PubMed ID: 2858583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
